An interventional study of Minimally invasive hematoma evacuation in Intra Cerebral Hemorrhage and Stroke, sponsored by University of Melbourne. Recruiting at 13 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by University of Melbourne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Cerebral Hemorrhage with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Cerebral Hemorrhage · Australia.
Among the 20 studies in Cerebral Hemorrhage with a site in Australia, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 with no phase, and was the 15th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →5 of the 20 studies in Cerebral Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:
The George Institute · Sites in Australia
Ages 18+
The George Institute · Sites in Australia, China
Ages 18–80
Region Skane · Sites in Australia, United States, Canada and 5 more countries
Ages 18+
The George Institute · Sites in Australia, Canada
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 452 across the 18 interventional studies, 332 across the 2 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 9 most frequent:
University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.
University of Melbourne has 1 study filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Hemorrhage with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07231315The George InstituteINTERACT4 Expansion - Validation Study | 2027-03-01 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Cerebral Hemorrhage with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized controlled trial of ultra-early, minimally invasive, hematoma evacuation versus standard care within 8 hours of intracerebral hemorrhage. Patients presenting to the emergency department with stroke due to supratentorial, spontaneous intracerebral hemorrhage >20mL volume will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomized 50:50 using central computerized allocation to minimally invasive hematoma evacuation using the Aurora surgiscope and evacuator (Integra Lifesciences) versus standard medical therapy. The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design with seamless phase 2b-3 transition if the intermediate endpoint (successful hematoma evacuation) is met in analysis of the first 52 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 160 patients have completed 6 month follow-up (minimum sample size 240, maximum sample size 434).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
Procedure: Minimally invasive hematoma evacuation
Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
Dichotomized Modified Rankin Scale Score 0-3 vs. 4-6 at 6 months post-onset (Adjusted)
Modified Rankin Scale (mRS) 0-3 at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.
Time frame: 6 months post-stroke
Dichotomized Modified Rankin Scale Score 0-2 or no change from baseline vs. 3-6 at 6 months post-onset (adjusted)
Modified Rankin Scale (mRS) 0-2 or no change from baseline at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
Time frame: 6 months post-stroke
Ordinal analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted)
Ordinal analysis of Modified Rankin Scale Score (merging mRS 5-6) at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
Time frame: 6 months post-stroke
Utility-weighted analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted)
Utility-weighted analysis of Modified Rankin Scale Score at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
Time frame: 6 months post-stroke
Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted)
Reduction in hematoma volume at 24 hours \>70% or \<15mL residual volume, adjusted for immediate pre-treatment ICH volume
Time frame: 24 hours post-randomization
Proportion of patients with early neurological improvement at 7 days (adjusted)
Proportion of patients with ≥8 point reduction in National Institutes of Health Stroke Scale (NIHSS) score or reaching 0-1 at 7 days (or at discharge if earlier) adjusted for baseline NIHSS and age
Time frame: 7 days post-stroke
Safety: Death due to any cause at 6 months (adjusted)
Death due to any cause at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.
Time frame: 6 months post-stroke
Safety: Hematoma growth or reaccumulation at 24 hours
Hematoma growth or reaccumulation defined as \>33% or \>6mL increased volume between baseline and 24 hour scans (or in the intervention arm a hematoma volume on the follow-up scan exceeding the immediate pre-treatment volume), adjusted for the pre-treatment ICH volume.
Time frame: 24 hours post-randomization
Intermediate outcome measure (primary outcome measure for Phase 2b component): Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted)
Intermediate outcome measure (primary outcome measure for the Phase 2b component to be analysed for the first 52 patients): Reduction in hematoma volume at 24 hours \>70% or \<15mL residual volume, adjusted for immediate pre-treatment ICH volume
Time frame: 24 hours post-randomization
Patient Reported Outcomes Measurement Information System (PROMIS10)
Time frame: 6 and 12 months post-stroke
Modified Rankin Scale (mRS) 0-2, 0-3, ordinal and utility-weighted analysis at 12 months
Time frame: 12 months post-stroke
Assessment of Quality of Life (EQ5D) at 12 months
Assessment of Quality of Life (EQ5D) at 12 months (mapped to mRS at baseline)
Time frame: 12 months post-stroke
Length of stay in intensive care unit, acute hospital, acute hospital and rehabilitation
Time frame: 6 months post-stroke
Home time - time spent at home in the first 6 months
Time frame: 6 months post-stroke
Plan to share: Yes — Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive (http://www.virtualtrialsarchives.org/vista/) 2 years after the publication of the primary manuscript. Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee.
Time frame: 2 years after the publication of the primary manuscript
Access criteria: Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee.
No publications or documents are linked to this record.
Started Nov 2020 (actual). Primary completion is estimated for Dec 2027, 85 months after the start.
Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 85 months is above that.
Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Melbourne